XTANDI ENZALUTAMIDE 40 MG 112 CAPSULES TORRINO UK
Xtandi is indicated for the treatment of adult men with castration-resistant metastatic prostate cancer (CRPC), asymptomatic or mildly symptomatic after the failure of androgen deprivation therapy, in whom chemotherapy is not yet clinically indicated, the treatment of adult men with Metastatic CRPC in which the disease has progressed during or at the end of docetaxel therapy.
All our products are delivered in a sealed package
Al our products are delivered within 24 hours
We accept returns within 14 days from the purchase
A large percentage of patients with prostate cancer resort to androgen deprivation therapy. This happens in cases where the tumor is already at an advanced stage at diagnosis (and therefore not suitable for a local remedial therapy such as radical surgery or radiotherapy) or in those cases where a recurrence occurs following a local treatment performed for healing purposes which cannot be managed with a second local "rescue" treatment. Androgen deprivation therapy aims to cancel the action of testosterone, a hormone essential for the growth and replication of prostate cancer cells. Until recently, the drugs available for this therapy were LH-RH analogues (such as leuprolein and triptorelin), LH-RH inhibitors (degarelix), antiandrogens (bicalutamide, flutamide, nilutamide, cyproterone acetate) and estrogens ( diethylstilbestrol). In recent years the scenario has changed and today some new drugs have shown good efficacy; one of these is enzalutamide, a last-generation antiandrogen drug that can be administered orally. Based on the first available studies, it appears to have high therapeutic efficacy and could play a fundamental role in the treatment of prostate tumors that have become refractory to "traditional" hormone therapy.